Summit Therapeutics (NASDAQ: SMMT)
Summit Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Summit Therapeutics Company Info
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
News & Analysis
Why Summit Therapeutics Stock Crushed the Market This Week
The company was a standout in the biotech field, rising by nearly 23% over the period.
Why Shares of Summit Therapeutics Slumped on Tuesday
The company's shares have been falling since it announced earnings late last week.
Why Shares of Summit Therapeutics Soared This Week
Summit Therapeutics advanced its lead therapy into two phase 3 trials to treat non-small cell lung cancer.
Why Summit Therapeutics Shares Soared This Week
The clinical-stage biopharma stock has been rising all year.
Why Summit Therapeutics Stock Is Skyrocketing This Week
The company announced an important licensing deal.
Why Summit Therapeutics Stock Popped Today
The biotech's recent upward momentum is showing no signs of fading.
Why Summit Therapeutics Stock Is Soaring Today
Investors responded enthusiastically to key insider buying.
Why Summit Therapeutics Stock Is Tumbling Today
The company just revealed disappointing phase 3 trial results for its only clinical-stage drug candidate.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.